Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 790-801
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Global epidemiology of cirrhosis — aetiology, trends and predictions
Daniel Q. Huang, Norah A. Terrault, Frank Tacke, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 388-398
Open Access | Times Cited: 359
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis
Jingxuan Quek, Kai En Chan, Zhen Yu Wong, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 20-30
Closed Access | Times Cited: 326
MAFLD: How is it different from NAFLD?
Cameron Gofton, Yadhavan Upendran, Ming‐Hua Zheng, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S17-S31
Open Access | Times Cited: 223
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 841-850
Open Access | Times Cited: 158
Non-alcoholic fatty liver disease: Definition and subtypes
Seulki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S5-S16
Open Access | Times Cited: 102
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 82
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang‐Chin Huang, Chun‐Jen Liu
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 320-331
Open Access | Times Cited: 42
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung‐Wan Lee, Eun Seok Kang, et al.
Metabolism (2024) Vol. 152, pp. 155789-155789
Closed Access | Times Cited: 17
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S43-S57
Open Access | Times Cited: 55
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1097-1097
Open Access | Times Cited: 25
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeong Jun Song
Nutrients (2023) Vol. 15, Iss. 18, pp. 3970-3970
Open Access | Times Cited: 22
Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Alejandra Zazueta, Lucía Valenzuela-Pérez, Nicolás Ortiz‐López, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4387-4387
Open Access | Times Cited: 10
Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis
Mark Muthiah, Cheng Han Ng, Kai En Chan, et al.
Annals of Hepatology (2022) Vol. 28, Iss. 1, pp. 100762-100762
Open Access | Times Cited: 36
Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD – An Umbrella Overview of Systematic Review of Meta-Analysis
Jieling Xiao, Cheng Han Ng, Kai En Chan, et al.
Journal of Clinical and Experimental Hepatology (2022) Vol. 13, Iss. 4, pp. 656-665
Open Access | Times Cited: 31
Markers of insulin resistance associated with non-alcoholic fatty liver disease in non-diabetic population
Pei Zeng, Xiangsheng Cai, Xiaozhou Yu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
Byeong Geun Song, Sung C. Choi, Myung Ji Goh, et al.
JHEP Reports (2023) Vol. 5, Iss. 9, pp. 100810-100810
Open Access | Times Cited: 18
Global research trends on gut microbiota and metabolic dysfunction-associated steatohepatitis: Insights from bibliometric and scientometric analysis
Naqash Alam, Linying Jia, Ao Cheng, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 5
The Spectrum and Impact of Metabolic Dysfunction in MAFLD: A Longitudinal Cohort Analysis of 32,683 Overweight and Obese Individuals
Kai En Chan, Cheng Han Ng, Clarissa Elysia Fu, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 21, Iss. 10, pp. 2560-2569.e15
Closed Access | Times Cited: 24
The relationship between metabolic dysfunction‐associated fatty liver disease and low muscle mass in an asymptomatic Korean population
Ji Yeon Seo, Eun Ju Cho, Min Joo Kim, et al.
Journal of Cachexia Sarcopenia and Muscle (2022) Vol. 13, Iss. 6, pp. 2953-2960
Open Access | Times Cited: 22
Association of composite dietary antioxidant index and muscle mass in individuals with metabolic associated fatty liver disease
Jing Guo, Lin Shi, Yan Sun
Clinics and Research in Hepatology and Gastroenterology (2024) Vol. 48, Iss. 2, pp. 102284-102284
Closed Access | Times Cited: 4
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access
The clinical impact of an extra virgin olive oil enriched mediterranean diet on metabolic syndrome: Lights and shadows of a nutraceutical approach
Aurelio Seidita, Maurizio Soresi, Lydia Giannitrapani, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 20
Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
Nan Yao, Yixue Yang, Xiaotong Li, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 19
Correlation between thyroid function, sensitivity to thyroid hormones and metabolic dysfunction-associated fatty liver disease in euthyroid subjects with newly diagnosed type 2 diabetes
Xiaodan Zhang, Yimei Chen, Huiyu Ye, et al.
Endocrine (2022) Vol. 80, Iss. 2, pp. 366-379
Closed Access | Times Cited: 19
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease
Ho Soo Chun, Minjong Lee, Jae Seung Lee, et al.
Liver International (2022) Vol. 43, Iss. 3, pp. 608-625
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top